American Thoracic Society - Sanofi Investor Call
Treatment-Emergent Adverse Events
in the Safety Population*
Placebo
Dupilumab
(N = 470)
(N = 469)
Most common TEAEs (≥ 5%), no. (%)
45 (9.6)
44 (9.4)
Nasopharyngitis
32 (6.8)
38 (8.1)
Headache
Upper respiratory tract infection
46 (9.8)
37 (7.9)
Chronic obstructive pulmonary disease1
28 (6.0)
27 (5.8)
17 (3.6)
25 (5.3)
Diarrhea
16 (3.4)
24 (5.1)
Back pain
27 (5.7)
19 (4.1)
COVID-19
Hypertension
28 (6.0)
17 (3.6)
*
The safety population consisted of all patients who received at least one dose or part of a dose of the
investigational medicinal product, analyzed according to the treatment received. One patient assigned to the placebo
group inadvertently received dupilumab so was included in the dupilumab safety population.
1. All COPD-related hospitalizations are initially reported as SAEs (investigator reported)
ATS 2023
31View entire presentation